Neueste Erkenntnisse
(2008) betreffend Hormonersatztherapie und Brustkrebs: Patientinnen, die vor der
Diagnose Brustkrebs Hormonersatzpräparate (Kombination von Östrogen und
Progesteron) eingenommen haben, haben statistisch signifikant bessere
Überlebenschancen und auch ein geringeres Risiko am Krebs zu versterben
gegenüber jenen Frauen, die keine Hormone genommen haben. Lesen Sie bitte dazu
die folgende Originalarbeit:
Pre-Breast Cancer Use of Oestrogen-Progestin Hormone
Replacement Therapy Appears to Lower Mortality Risk
By Bruce Sylvester
SAN ANTONIO, Tex --
December 14, 2008 -- Women who use combination oestrogen-progestin
hormone-replacement therapy (HT) prior to a breast-cancer diagnosis are less
likely to die from the cancer, researchers reported at the 31st Annual San
Antonio Breast Cancer Symposium (SABCS).
“The combination hormone therapy taken before diagnosis improved survival, and
it was a statistically significant finding,” said lead investigator Sarah
Marshall, MA, University of California at Irvine, Irvine, California, speaking
here on December 13.
Ms. Marshall and colleagues noted that breast-cancer survival appears to be
improved with prediagnostic use of HT, but it has not been clear whether this is
due to a direct effect of HT or because HT leads to the development of tumour
types with a better prognosis. “It is therefore important to examine whether the
association between HT use and survival still remains after adequate adjustment
for tumour characteristics,” they said.
The investigators extracted data from the ongoing California Teachers Study,
including data on 133,479 women. The data set included 2,783 postmenopausal
women whose HT use was documented and who were also diagnosed with an incident
primary invasive breast cancer after joining the cohort in 1995-1996. These
women were followed until death or the end of 2005.
The investigators identified incident cancers and tumour characteristics through
annual linkage with the statewide California Cancer Registry. HT and other
covariates were self-reported on a baseline questionnaire. The researchers
estimated the relative risk (RR) of breast-cancer death by stratifying according
to age in years, and using age in days from breast-cancer diagnosis as the time
scale.
They reported that during the follow-up period, 159 (5.7%) women died of breast
cancer.
They also reported that among the women who used prediagnosis oestrogen-
progestin, the risk of dying from their breast cancer was reduced by 63%
compared with women who did not use hormones (RR = 0.37; 0.24-0.57, P < .0001);
there was a 36% reduction for those who used oestrogen only (RR = 0.64;
0.43-0.95).
Adjusting for the fact that women who use hormones tend to be leaner, exercise
more, and smoke less, as well as adjusting for tumour characteristics and
treatment received, the investigators still found a 47% reduced risk of
breast-cancer death among the women who used oestrogen-progestin (RR = 0.53;
0.33-0.84) and an 18% among [oestrogen-only] subjects (RR = 0.82; 0.53-1.27).
The researchers concluded that the “use of oestrogen-progestin before diagnosis
was associated with a reduced risk of death due to breast cancer. Use of
oestrogen was also associated with reduced breast-cancer mortality, although the
association was not statistically significant after adjustment for indicators of
general health, characteristics of tumour, and treatment.”
[Presentation title: Hormone Therapy Use Before Diagnosis and Breast Cancer
Survival in the California Teachers Study. Abstract 65]
|
